Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Rashmi Kumari

UNCOVERED: Gilead sciences q2 2024 earnings what to expect - The Untold Story

Based in Foster City, California, Gilead Sciences, Inc. (GILD) is a global leader in biopharmaceuticals, renowned for its pioneering advancements in antiviral therapies. With a market cap of $91.32 billion, Gilead is recognized for its innovative portfolio that enhances patient care through cutting-edge treatments for diseases like HIV, hepatitis, and cancer. The company is set to announce its fiscal Q2 earnings results after the market closes on Thursday, Aug. 8.

Ahead of the event, analysts expect GILD to report a profit of $1.58 per share, up 17.9% from $1.34 per share in the year-ago quarter. In the last four quarters, the company surpassed Wall Street’s bottom-line estimates in two and missed on two occasions.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.